Ones To Watch News
Refine Search
Pharmaceutical
Philadelphia-based biotech Vivodyne has raised $40 million in series A funding to advance its fully robotic, AI-powered platform that tests drug candidates on lab-grown human tissues. 30 May 2025
Biotechnology
Shares in US biotech Intellia Therapeutics slid by a quarter on Thursday following a safety update from its late-stage trial of a CRISPR-based treatment for a rare heart disease. 30 May 2025
Biotechnology
Vima Therapeutics, a Cambridge, USA-based clinical-stage biotechnology company focused on oral therapies for movement disorders, has launched with a $60 million Series A financing. 30 May 2025
Pharmaceutical
The US Food and Drug Administration (FDA) has identified a potential path forward for elamipretide for the treatment of Barth syndrome, Stealth BioTherapeutics revealed today. 29 May 2025
Biotechnology
US biotech iTeos Therapeutics is preparing to wind down its operations and halt clinical work, as it looks to sell off assets and return value to investors following a major blow to its lead immunotherapy program. 29 May 2025
Pharmaceutical
Spero Therapeutics is making headlines as its stock experienced a remarkable 244% surge to $2.35 yesterday, on news of positive clinical trial results. 29 May 2025
Biotechnology
Sino-American biotech BeiGene has now effected its previously announced transition, becoming BeOne Medicines and redomiciling to Switzerland, marking a significant milestone in the company’s evolution. 29 May 2025
Biotechnology
German drug developer InflaRx saw its US-traded shares plunge 55% to $0.82 in pre-market activity today, as it announced that the Independent Data Monitoring Committee (IDMC) conducting the unblinded interim analysis for the Phase III trial for vilobelimab in pyoderma gangrenosum (PG), recommended that the trial be stopped due to futility. 28 May 2025
Pharmaceutical
US biotech GRIN Therapeutics has secured $140 million in Series D funding and signed a licensing deal with Italy's Angelini Pharma that could bring in more than $500 million in future payments tied to its lead investigational therapy, radiprodil. 28 May 2025
Pharmaceutical
New York-based neurosciences company Gilgamesh Pharmaceuticals yesterday announced Phase IIa results for GM-2505, a novel, rapid-acting 5-HT2A receptor agonist and 5-HT releaser in development for the treatment of patients with moderate-to-severe major depressive disorder (MDD). 28 May 2025
Biotechnology
US biotech Lexeo Therapeutics has secured $80 million from a private placement, giving the company enough capital to push ahead with its cardiac gene therapy pipeline and fund operations into 2028. 28 May 2025
Pharmaceutical
US pharma major Eli Lilly has announced a definitive agreement to acquire SiteOne Therapeutics, a private biotechnology company developing small molecule inhibitors of sodium channels to treat pain and other neuronal hyperexcitability disorders. 28 May 2025
Biotechnology
Biotech major Biogen and fellow Cambridge, USA-based City Therapeutics, today announced a strategic collaboration to develop select novel RNA interference (RNAi)-based therapies. 27 May 2025
Pharmaceutical
US biotech Syndeio Biosciences has launched with over $90 million in funding and a pipeline of synapse-targeting neurotherapies aimed at treating major depressive disorder, Alzheimer’s disease, and other central nervous system (CNS) conditions. 27 May 2025
Pharmaceutical
Danish privately-held drugmaker MC2 Therapeutics today announced the appointment of Trine Ahlgreen as chief executive (CEO). 27 May 2025
Biotechnology
UK biotech Nucleome Therapeutics has appointed Bhavna Hunjan as chief business officer, a move that strengthens its leadership as it advances its pipeline of antibody therapies for inflammatory diseases. 27 May 2025
Pharmaceutical
Privately-held German radiopharmaceutical company Isotope Technologies Munich (ITM) has announced a debt financing agreement for up to $262.5 million from funds managed by Blue Owl Capital. 27 May 2025
Biotechnology
Shared of Ireland-headquartered Prothena Corporation plummeted almost 24% to $5.01 in post-market activity on Friday, when the company announced the Phase III AFFIRM-AL clinical trial evaluating birtamimab in patients with amyloid light chain (AL) amyloidosis did not meet its primary endpoint (HR=0.915, p-value=0.7680). 26 May 2025
Biosimilars
South Korea has launched the Priority Infectious Disease Pandemic Preparedness Rapid R&D Support Program, led by the Korea Disease Control and Prevention Agency (KDCA) in collaboration with SK bioscience. 26 May 2025
Biotechnology
This week on The Pharma Letter Podcast, we’re joined by Quin Wills, co-founder and chief scientific officer of UK biotech Ochre Bio. 22 May 2025
Pharmaceutical
Philadelphia-based biotech Vivodyne has raised $40 million in series A funding to advance its fully robotic, AI-powered platform that tests drug candidates on lab-grown human tissues. 30 May 2025
Biotechnology
Shares in US biotech Intellia Therapeutics slid by a quarter on Thursday following a safety update from its late-stage trial of a CRISPR-based treatment for a rare heart disease. 30 May 2025
Biotechnology
Vima Therapeutics, a Cambridge, USA-based clinical-stage biotechnology company focused on oral therapies for movement disorders, has launched with a $60 million Series A financing. 30 May 2025
Pharmaceutical
The US Food and Drug Administration (FDA) has identified a potential path forward for elamipretide for the treatment of Barth syndrome, Stealth BioTherapeutics revealed today. 29 May 2025
Biotechnology
US biotech iTeos Therapeutics is preparing to wind down its operations and halt clinical work, as it looks to sell off assets and return value to investors following a major blow to its lead immunotherapy program. 29 May 2025
Pharmaceutical
Spero Therapeutics is making headlines as its stock experienced a remarkable 244% surge to $2.35 yesterday, on news of positive clinical trial results. 29 May 2025
Biotechnology
Sino-American biotech BeiGene has now effected its previously announced transition, becoming BeOne Medicines and redomiciling to Switzerland, marking a significant milestone in the company’s evolution. 29 May 2025
Biotechnology
German drug developer InflaRx saw its US-traded shares plunge 55% to $0.82 in pre-market activity today, as it announced that the Independent Data Monitoring Committee (IDMC) conducting the unblinded interim analysis for the Phase III trial for vilobelimab in pyoderma gangrenosum (PG), recommended that the trial be stopped due to futility. 28 May 2025
Pharmaceutical
US biotech GRIN Therapeutics has secured $140 million in Series D funding and signed a licensing deal with Italy's Angelini Pharma that could bring in more than $500 million in future payments tied to its lead investigational therapy, radiprodil. 28 May 2025
Pharmaceutical
New York-based neurosciences company Gilgamesh Pharmaceuticals yesterday announced Phase IIa results for GM-2505, a novel, rapid-acting 5-HT2A receptor agonist and 5-HT releaser in development for the treatment of patients with moderate-to-severe major depressive disorder (MDD). 28 May 2025
Biotechnology
US biotech Lexeo Therapeutics has secured $80 million from a private placement, giving the company enough capital to push ahead with its cardiac gene therapy pipeline and fund operations into 2028. 28 May 2025
Pharmaceutical
US pharma major Eli Lilly has announced a definitive agreement to acquire SiteOne Therapeutics, a private biotechnology company developing small molecule inhibitors of sodium channels to treat pain and other neuronal hyperexcitability disorders. 28 May 2025
Biotechnology
Biotech major Biogen and fellow Cambridge, USA-based City Therapeutics, today announced a strategic collaboration to develop select novel RNA interference (RNAi)-based therapies. 27 May 2025
Pharmaceutical
US biotech Syndeio Biosciences has launched with over $90 million in funding and a pipeline of synapse-targeting neurotherapies aimed at treating major depressive disorder, Alzheimer’s disease, and other central nervous system (CNS) conditions. 27 May 2025
Pharmaceutical
Danish privately-held drugmaker MC2 Therapeutics today announced the appointment of Trine Ahlgreen as chief executive (CEO). 27 May 2025
Biotechnology
UK biotech Nucleome Therapeutics has appointed Bhavna Hunjan as chief business officer, a move that strengthens its leadership as it advances its pipeline of antibody therapies for inflammatory diseases. 27 May 2025
Pharmaceutical
Privately-held German radiopharmaceutical company Isotope Technologies Munich (ITM) has announced a debt financing agreement for up to $262.5 million from funds managed by Blue Owl Capital. 27 May 2025
Biotechnology
Shared of Ireland-headquartered Prothena Corporation plummeted almost 24% to $5.01 in post-market activity on Friday, when the company announced the Phase III AFFIRM-AL clinical trial evaluating birtamimab in patients with amyloid light chain (AL) amyloidosis did not meet its primary endpoint (HR=0.915, p-value=0.7680). 26 May 2025
Biosimilars
South Korea has launched the Priority Infectious Disease Pandemic Preparedness Rapid R&D Support Program, led by the Korea Disease Control and Prevention Agency (KDCA) in collaboration with SK bioscience. 26 May 2025
Biotechnology
This week on The Pharma Letter Podcast, we’re joined by Quin Wills, co-founder and chief scientific officer of UK biotech Ochre Bio. 22 May 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze